STOCK TITAN
  1. Home
  2. Sec-filings
  3. FTH
  4. [Form 4] Sensei Biotherapeutics, Inc. Insider Trading Activity

Faeth Therapeutics (FTH) CFO adds 15,641 shares via trust purchases

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Faeth Therapeutics, Inc.’s Chief Financial Officer Brian C. Stephenson reported multiple indirect open-market purchases of the company’s common stock. Over June 24 and June 26, 2026, a revocable trust associated with him bought a total of 15,641 shares at prices ranging from about $23.61 to $27.77 per share. Following these transactions, the trust held 33,054 shares of Faeth Therapeutics common stock. The shares are held by the Brian Stephenson Revocable Trust, where he is sole trustee with sole voting and investment power, while he disclaims beneficial ownership except to the extent of his pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider STEPHENSON BRIAN C
Role Chief Financial Officer
Bought 15,641 shs ($401K)
Type Security Shares Price Value
Purchase Common Stock 580 $23.61 $14K
Purchase Common Stock 4,212 $24.90 $105K
Purchase Common Stock 1,358 $25.55 $35K
Purchase Common Stock 100 $26.39 $3K
Purchase Common Stock 2,891 $25.22 $73K
Purchase Common Stock 3,000 $25.98 $78K
Purchase Common Stock 3,400 $26.98 $92K
Purchase Common Stock 100 $27.77 $3K
Holdings After Transaction: Common Stock — 27,384 shares (Indirect, See footnote)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.50 to $25.435, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.58 to $26.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.61 to $27.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.27 to $24.1663, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.27 to $25.2405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.335 to $26.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Total shares purchased 15,641 shares Net open-market buys reported in Form 4
Post-transaction holdings 33,054 shares Indirect common stock held by revocable trust
Highest reported price $27.77 per share Individual open-market purchase price on June 24, 2026
Lowest reported price $23.61 per share Individual open-market purchase price on June 26, 2026
Number of buy transactions 8 transactions Non-derivative open-market purchases of common stock
Transaction dates June 24 and 26, 2026 Dates of reported open-market purchases
open-market purchase financial
"transaction_action: "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Revocable Trust financial
"These shares are held directly by the Brian Stephenson Revocable Trust"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of the shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest therein."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
STEPHENSON BRIAN C
(Last)(First)(Middle)
C/O FAETH THERAPEUTICS, INC.
701 TILLERY STREET #12 #1010
(Street)
AUSTIN TEXAS 78702
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Faeth Therapeutics, Inc. [ FTH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/24/2026P2,891A$25.22(1)20,304ISee footnote(2)
Common Stock06/24/2026P3,000A$25.98(3)23,304ISee footnote(2)
Common Stock06/24/2026P3,400A$26.98(4)26,704ISee footnote(2)
Common Stock06/24/2026P100A$27.7726,804ISee footnote(2)
Common Stock06/26/2026P580A$23.61(5)27,384ISee footnote(2)
Common Stock06/26/2026P4,212A$24.9(6)31,596ISee footnote(2)
Common Stock06/26/2026P1,358A$25.55(7)32,954ISee footnote(2)
Common Stock06/26/2026P100A$26.3933,054ISee footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.50 to $25.435, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
2. These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.58 to $26.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.61 to $27.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.27 to $24.1663, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.27 to $25.2405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
7. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.335 to $26.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
/s/ Josiah Craver, Attorney-in-Fact06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Faeth Therapeutics (FTH) disclose in this Form 4?

Faeth Therapeutics disclosed that its Chief Financial Officer, Brian C. Stephenson, reported indirect open-market purchases of common stock through a revocable trust on June 24 and June 26, 2026, increasing that trust’s holdings to 33,054 shares after the reported transactions.

How many Faeth Therapeutics (FTH) shares did the CFO buy and at what prices?

The CFO’s associated revocable trust bought a total of 15,641 Faeth Therapeutics common shares. The individual transactions were executed at reported prices between approximately $23.61 and $27.77 per share, reflecting multiple open-market purchases across two trading days in June 2026.

How are the Faeth Therapeutics (FTH) shares held by CFO Brian Stephenson structured?

The reported shares are held by the Brian Stephenson Revocable Trust. Brian Stephenson is the sole trustee and has sole voting and investment power over the securities, but he disclaims beneficial ownership of the shares except to the extent of his pecuniary interest in the trust.

What is the CFO’s reported indirect ownership in Faeth Therapeutics (FTH) after these trades?

After the reported open-market purchases, the Brian Stephenson Revocable Trust held 33,054 shares of Faeth Therapeutics common stock indirectly attributable to CFO Brian Stephenson, as shown in the post-transaction ownership column of the Form 4 transaction table for these non-derivative securities.

Were any derivatives or options reported in this Faeth Therapeutics (FTH) Form 4?

No derivative securities were listed in the derivative section for this Form 4. All reported transactions involved non-derivative Faeth Therapeutics common stock, and the derivativeSummary section for the filing was empty, indicating no options or similar instruments in this particular report.

How many separate open-market trades did the Faeth Therapeutics (FTH) CFO report?

The filing shows eight separate open-market purchase transactions in Faeth Therapeutics common stock. These trades occurred on June 24 and June 26, 2026, with each line item reflecting a specific share amount and weighted average price for that portion of the overall buying activity.